---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011615"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:57:13.284702+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience reports FY2023 net loss $30.1M, cash $10.5M; XACIATO launched, Ovaprene Phase 3 recruiting

## Summary
- Net loss of $30.1M for FY2023; revenue of $2.8M from XACIATO milestone payments.
- Cash and equivalents $10.5M at Dec 31, 2023; received $4.7M in grant funding and $17M in offerings/financing.
- XACIATO launched in U.S. via Organon; Daré eligible for double-digit royalties and up to $180M milestones.
- Ovaprene Phase 3 pivotal study recruiting at 17 U.S. sites; non-hormonal monthly contraceptive candidate.
- Sildenafil Cream completed Phase 2b; FDA feedback on Phase 3 design expected in Q2 2024.

## SEC filing metadata
- accession: 0001493152-24-011615
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315224011615/0001493152-24-011615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315224011615/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011615
- JSON: https://secwatch.observer/filing/0001493152-24-011615.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011615.txt

## Key facts
- Earnings Releases
  Dare Bioscience, Inc. reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 28, 2024, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315224011615/0001493152-24-011615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.